Teva Pharmaceutical Industries (TEVA) Other Working Capital Changes (2009 - 2026)

Teva Pharmaceutical Industries (TEVA) has reported Other Working Capital Changes for 18 consecutive years, with -$54.0 million the latest figure, recorded in Q1 2026.

• Quarterly Other Working Capital Changes fell 440.0% year-over-year to -$54.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $37.0 million (down 93.24% YoY) and the FY2025 annual result came in at $81.0 million, down 85.54% from the prior year.
• Other Working Capital Changes eased to -$54.0 million in Q1 2026 per TEVA's latest filing, from -$41.0 million in the prior quarter.
• Over the last five years, Other Working Capital Changes for TEVA reached as high as $700.0 million in Q1 2025 and fell as low as -$1.9 billion in Q4 2023.
• A 5-year average of -$117.5 million and a median of -$93.0 million in 2022 frame the typical range for Other Working Capital Changes.
• Annual changes were most pronounced in 2022 — Other Working Capital Changes plunged 3666.67% — and 2024, when it surged 5033.33%.
• Year by year, Other Working Capital Changes stood at $26.0 million in 2022, then jumped by 65.38% to $43.0 million in 2023, then tumbled by 186.05% to -$37.0 million in 2024, then slipped by 10.81% to -$41.0 million in 2025, then plunged by 31.71% to -$54.0 million in 2026.
• According to Business Quant data, Other Working Capital Changes over the past three periods registered -$54.0 million, -$41.0 million, and $27.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.